Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 14/20 | 0.42 |
| ▸ | SYK | P43405 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1890842 | 0.95 | JAK3 (0.46) | JAK3SYKKCNH2CYP2C9 | |
| SCHEMBL1892873 | 0.85 | JAK3 (0.49) | JAK3SYKMAPK1KCNH2CYP2C9 | |
| SCHEMBL1890511 | 0.85 | JAK3 (0.53) | JAK3SYKMAPK1CYP2C9 | |
| SCHEMBL1892369 | 0.84 | JAK3 (0.48) | JAK3SYKKCNH2CYP2C9 | |
| SCHEMBL1893820 | 0.84 | JAK3 (0.48) | JAK3SYKKCNH2CYP2C9 | |
| SCHEMBL1894973 | 0.83 | JAK3 (0.47) | JAK3SYKKCNH2CYP2C9 | |
| SCHEMBL1892554 | 0.83 | JAK3 (0.49) | JAK3SYKKCNH2 | |
| SCHEMBL1893271 | 0.82 | JAK3 (0.46) | JAK3 | |
| SCHEMBL1888859 | 0.82 | JAK3 (0.46) | JAK3SYKKCNH2CYP2C9 | |
| SCHEMBL2281665 | 0.81 | JAK3 (0.51) | JAK3SYKMAPK1KCNH2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | claimed |
| US-7939531-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-05-10 | — | — | US | disclosed |
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215750-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK2 | JAK3 7/4885SYK 1/4885MAPK1 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.